

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**華潤醫藥集團有限公司**

**China Resources Pharmaceutical Group Limited**

*(Incorporated in Hong Kong with limited liability)*

(Stock Code: 3320)

## **INSIDE INFORMATION**

# **REGISTRATION AND COMPLETION OF THE PUBLIC ISSUANCE OF THE 2023 FIRST TRANCHE CORPORATE BONDS IN THE PRC**

This announcement is made pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) of Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board of directors (the “**Board**”) of China Resources Pharmaceutical Group Limited (the “**Company**”) is pleased to announce that China Resources Pharmaceutical Commercial Group Company Limited (華潤醫藥商業集團有限公司) (“**CR Pharmaceutical Commercial**”), a wholly-owned subsidiary of the Company, has received an Approval with respect to the Registration for the Public Issuance of Corporate Bonds by CR Pharmaceutical Commercial to Qualified Investors (《關於同意華潤醫藥商業集團有限公司向專業投資者公開發行公司債券註冊的批覆》) (Zheng Jian Xu Ke [2023] No. 910) (the “**Approval**”) from the China Securities Regulatory Commission, approving the proposed public issuance of corporate bonds by CR Pharmaceutical Commercial to qualified investors in the People’s Republic of China (the “**PRC**”) in an aggregate principal amount of not more than RMB2 billion (the “**Corporate Bonds**”). The Approval shall be effective for a period of 24 months from the date of registration, during which CR Pharmaceutical Commercial may issue the Corporate Bonds in tranches.

The Board is pleased to announce that CR Pharmaceutical Commercial has issued the 2023 first tranche of Corporate Bonds in the PRC. The issuance size is RMB2 billion with a term of three years and a coupon rate of 3.09% per annum. The net proceeds raised from the issuance of the first tranche of the Corporate Bonds will be used for the repayment of interest-bearing debt.

**Shareholders of the Company and potential investors are advised to exercise caution when dealing in the securities of the Company.**

By order of the Board  
**China Resources Pharmaceutical Group Limited**  
**Han Yuewei**  
*Chairman*

Shenzhen, 8 May 2023

*As at the date of this announcement, the Board comprises Mr. Han Yuewei as chairman and non-executive Director, Mr. Bai Xiaosong, Mr. Tao Ran and Mdm. Weng Jingwen as executive Directors, Mr. Lin Guolong, Mdm. Guo Wei, Mr. Hou Bo and Mdm. Jiao Ruifang as non-executive Directors and Mdm. Shing Mo Han Yvonne, Mr. Kwok Kin Fun, Mr. Fu Tingmei and Mr. Zhang Kejian as independent non-executive Directors.*